Stockholm, Sweden

13-16 March 2024

Eurogin 2024

“Primary HPV mRNA screening with different genotype combinations to enhance cervical cancer prevention in South African women”

Prof. MD. Greta Dreyer

Cancers. 2023; 15(22):5453. https://doi.org/10.3390/cancers15225453

Sørbye S, Falang BM, Botha H, Snyman L, van der Merwe FH, Visser C, Richter K, Dreyer G

“Performance of a 7-type HPV mRNA test in triage of HPV DNA primary screen positive women compared to liquid-based cytology”

MD. PhD. Sveinung Wergeland Sørbye

J. Mol. Pathol. 2023, 4, 69–8 https://doi.org/10.3390/jmp4020008

Sveinung W. Sørbye, Bente M. Falang, Mona Antonsen

Dusselldorf Germany,
3-5 April 2022:

EUROGIN 2022, International multidisiplinary HPV congress

“7-Type HPV mRNA test in triage of HPV DNA positive women”
MD.PhD S.W.Sørbye

“SELF- vs CLINICIAN collected samples for the detection of HPV by 14-type DNA and 7-type mRNA tests, a Mexican trial”
Dr C. E. Aranda Flores

Trade Fair and Congress Center of Malaga- FYCMA, Málaga, Spain

11-13 November 2021:

Congress: AEPCC “Annual Congress of the Spanish Association of Cervical Pathology and Colposcopy”

“Relevance and importance of HPV mRNA E6/E7 biomarkers in the prevention of cervical cancer”
MD.PhD S.W.Sørbye

Lisbon portugal,
2-5 December 2018:

EUROGIN 2018, International multidisiplinary HPV congress

“A risk-based approach: co-testing 34,612 women with cytology and a 3-type HPV mRNA test”
MD.PhD S.W.Sørbye

“Primary cervical screening with a 5-type HPV E6/E7 mRNA test: Results of 10 years follow-up”
Prof. MD. F.E.Skjeldestad

“3-type HPV mRNA test in detection of CIN2+ in young women with normal cytology“
MD. K. Al-Shibli

“Is co-testing with a 3-type HPV MRNA test a better strategy for women 21-29 years than cytology only?“
MD.PhD S.W.Sørbye

“The added value of rescreening cytology normal samples with positive HPV mRNA test for the detection of CIN2+ in primary screening”
Prof. MD. F.E.Skjeldestad